{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["cannabidiol", "cannabidiol oil", "consumer product safety", "online medicinal products", "product labeling", "quality", "test purchase"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": [], "OtherID": [], "GeneralNote": [], "PMID": "38192407", "DateRevised": {"Year": "2024", "Month": "01", "Day": "10"}, "Article": {"Language": ["eng"], "ELocationID": ["1273540", "10.3389/fphar.2023.1273540"], "ArticleDate": [{"Year": "2023", "Month": "12", "Day": "14"}], "Journal": {"ISSN": "1663-9812", "JournalIssue": {"Volume": "14", "PubDate": {"Year": "2023"}}, "Title": "Frontiers in pharmacology", "ISOAbbreviation": "Front Pharmacol"}, "ArticleTitle": "Safety and risks of CBD oils purchased online: unveiling uncertain quality and vague health claims.", "Pagination": {"StartPage": "1273540", "MedlinePgn": "1273540"}, "Abstract": {"AbstractText": ["<b>Introduction:</b> The unmet need for highly effective, naturally derived products with minimal side effects results in the over-popularity of ever-newer medicinal plants. In the middle of 2010, products containing cannabidiol (CBD), one of the special metabolites of <i>Cannabis sativa</i>, started to gain popularity. For consumers and healthcare providers alike, the legal context surrounding the marketing of CBD products is not entirely clear, and the safety of using some products is in doubt. Companies in the online medicinal product market profit from the confusion around CBD oils. <b>Methods:</b> In our study, we employed a complex method known as risk-based safety mapping of the online pharmaceutical market, which included health claim content analysis of online stores, test purchases, and labeling and quantitative analysis of the CBD content. <b>Results:</b> There were discovered 16 online retailers selling an average of 2-7 goods and CBD oils with a concentration of 3%-5% (30-50\u00a0mg/mL) CBD. The majority (n/N = 10/16, 62.5%) displayed potential health-related benefits indirectly on their website, and in the case of one web shop (n/N = 1/16, 6.3%), we detected COVID-19-related use. Altogether, 30 types of purported \"indications\" were collected. A total of 12 CBD oil products were test-purchased from online retailers in December 2020. Upon evaluating the packaging and product information, we noticed that three products (n/N = 3/12, 25%) lacked instructions on use, hence increasing the risk of inappropriate application and dosing. The cannabidiol content was quantified using UHPLC. The measured CBD concentrations of the products ranged from 19.58\u00a0mg/mL to 54.09\u00a0mg/mL (mean 35.51\u00a0mg/mL, median 30.63\u00a0mg/mL, and SD \u00b1 12.57\u00a0mg/mL). One (8.33%) product was underlabeled, five (41.67%) were over-labeled, and only every second product (50%) was appropriately labeled based on the quantitative assessment of CBD concentration. <b>Discussion:</b> Further research and quality control are necessary to establish the regulatory context of the usage and classification of CBD and other cannabinoids in nonmedicinal products (e.g., food supplements), as authorities and policymakers worldwide struggle with the uncertainties surrounding CBD products."], "CopyrightInformation": "Copyright \u00a9 2023 Vida, Strauss, Bajtel, Kiss, Csupor and Fittler."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutics, Faculty of Pharmacy, University of P\u00e9cs, P\u00e9cs, Hungary."}], "LastName": "Vida", "ForeName": "R\u00f3bert Gy\u00f6rgy", "Initials": "RG"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutics, Faculty of Pharmacy, University of P\u00e9cs, P\u00e9cs, Hungary."}], "LastName": "Strauss", "ForeName": "Lilien Victoria", "Initials": "LV"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Pharmacognosy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary."}], "LastName": "Bajtel", "ForeName": "\u00c1kos", "Initials": "\u00c1"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Pharmacognosy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary."}], "LastName": "Kiss", "ForeName": "Tivadar", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Pharmacognosy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary."}, {"Identifier": [], "Affiliation": "Institute of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary."}, {"Identifier": [], "Affiliation": "Institute for Translational Medicine, Medical School, University of P\u00e9cs, P\u00e9cs, Hungary."}], "LastName": "Csupor", "ForeName": "Dezs\u0151", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutics, Faculty of Pharmacy, University of P\u00e9cs, P\u00e9cs, Hungary."}], "LastName": "Fittler", "ForeName": "Andr\u00e1s", "Initials": "A"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Pharmacol", "NlmUniqueID": "101548923", "ISSNLinking": "1663-9812"}, "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that they were editorial board members of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "\nAdelstone J. (2022). The duality of cannabis regulation according to the international Narcotics control board: a response to the report of the INCB for 2022. Available at: https://vicentellp.com/img/content/downloads/Vicente-LLP-Response-to-INCB-2022-Report-on-Cannabis-20230314.pdf (Accessed July 21, 2023)."}, {"Citation": "Amann L., Kruse E., Lazard A. J., Reboussin B. A., Wagoner K. G., Romero-Sandoval E. A. (2022). CBD retailers in NC promote CBD online to treat pain violating FDA rules about medical claims and offer low-CBD/high-price products. J. Pain Res. 15, 3847\u20133858. 10.2147/JPR.S384996", "ArticleIdList": ["10.2147/JPR.S384996", "PMC9741853", "36514481"]}, {"Citation": "\nAustralian Government Department of Health and Aged Care Therapeutic Goods Administration (2020). Review on the safety of low dose cannabidiol Version 1.0. Available at: https://www.tga.gov.au/sites/default/files/review-safety-low-dose-cannabidiol.pdf (Accessed July 21, 2023)."}, {"Citation": "Bajtel \u00c1., Kiss T., Csupor-L\u00f6ffler B., Szendrei K., Csupor D. (2021). Cannabis: medicine, food or illicit drug? Orv. Hetil. 162, 1808\u20131817. 10.1556/650.2021.32211", "ArticleIdList": ["10.1556/650.2021.32211", "34747360"]}, {"Citation": "Bansal S., Maharao N., Paine M. F., Unadkat J. D. (2020). Predicting the potential for cannabinoids to precipitate pharmacokinetic drug interactions via reversible inhibition or inactivation of major cytochromes P450. Drug Metab. Dispos. 48, 1008\u20131017. 10.1124/dmd.120.000073", "ArticleIdList": ["10.1124/dmd.120.000073", "PMC7543485", "32587099"]}, {"Citation": "Bhamra S. K., Desai A., Imani-Berendjestanki P., Horgan M. (2021). The emerging role of cannabidiol (CBD) products; a survey exploring the public\u2019s use and perceptions of CBD. Phytother. Res. 35, 5734\u20135740. 10.1002/ptr.7232", "ArticleIdList": ["10.1002/ptr.7232", "34350641"]}, {"Citation": "Bilbao A., Spanagel R. (2022). Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Med. 20, 259. 10.1186/s12916-022-02459-1", "ArticleIdList": ["10.1186/s12916-022-02459-1", "PMC9389720", "35982439"]}, {"Citation": "\nBlebea N., Costache T., Negres S. (2019). The qualitative and quantitative analysis of CBD in Hemp oils by UHPLC with PDA and applications. Ser. D. Animal Sci.\n62, 138\u2013142. Available at: https://animalsciencejournal.usamv.ro/pdf/2019/issue_1/Art20.pdf (Accessed July 21, 2023)."}, {"Citation": "Bonn-Miller M. O., Loflin M. J. E., Thomas B. F., Marcu J. P., Hyke T., Vandrey R. (2017). Labeling accuracy of cannabidiol extracts sold online. JAMA 318, 1708\u20131709. 10.1001/jama.2017.11909", "ArticleIdList": ["10.1001/jama.2017.11909", "PMC5818782", "29114823"]}, {"Citation": "\nCannabis and Cannabinoids Institute (2017). Warning for consumers of CBD and cannabis oils sold on the EU market. Available at: https://www.icci.science/en/article/news/warning-for-consumers-of-cbd-and-cannabis-oils-sold-on-the-eu-market/(Accessed July 21, 2023)."}, {"Citation": "\nDabrowska A., Johnson R., Green V., Sacco L. (2020). FDA regulation of cannabidiol (CBD) consumer products: overview and considerations for congress (R46189). Available at: https://crsreports.congress.gov/product/pdf/R/R46189 (Accessed July 21, 2023)."}, {"Citation": "Drug Enforcement Administration (2018). Schedules of controlled substances: placement in schedule V of certain FDA-approved drugs containing cannabidiol; corresponding change to permit requirements. Final order. Fed. Regist. 83, 48950\u201348953.", "ArticleIdList": ["30272400"]}, {"Citation": "Duchateau C., Canfyn M., Desmedt B., Kauffmann J.-M., St\u00e9vigny C., De Braekeleer K., et al. (2021). CBD oils on the Belgian market: a validated MRM GC-MS/MS method for routine quality control using QuEChERS sample clean up. J. Pharm. Biomed. Anal. 205, 114344. 10.1016/j.jpba.2021.114344", "ArticleIdList": ["10.1016/j.jpba.2021.114344", "34492452"]}, {"Citation": "Efsa Panel on Nutrition N. F., Nda F. A. (, Turck D., Bohn T., Castenmiller J., De Henauw S., et al. (2022). Statement on safety of cannabidiol as a novel food: data gaps and uncertainties. EFSA J. 20, e07322. 10.2903/j.efsa.2022.7322", "ArticleIdList": ["10.2903/j.efsa.2022.7322", "PMC9172591", "35686177"]}, {"Citation": "EMCDDA (2018). Medical use of cannabis and cannabinoids: questions and answers for policymaking. 10.2810/979004", "ArticleIdList": ["10.2810/979004"]}, {"Citation": "\nEuropean Commission (2023). Commission Regulation (EU) 2023/915 of 25 April 2023 on maximum levels for certain contaminants in food and repealing Regulation (EC) No 1881/2006. Official Journal of the European Union. Available at: https://eur-lex.europa.eu/eli/reg/2023/915 (Accessed July 21, 2023)."}, {"Citation": "\nEuropean Parliament (2006). Regulation (EC) No 1924/2006 of the European parliament and of the council of 20 december 2006 on nutrition and health claims made on foods. Official journal of the European union. Available at: http://data.europa.eu/eli/reg/2006/1924 (Accessed July 21, 2023)."}, {"Citation": "\nEuropean Parliament (2015). Regulation (EU) 2015/2283 of the European parliament and of the council of 25 november 2015 on novel foods, amending regulation (EU) No 1169/2011 of the European parliament and of the council and repealing regulation (EC) No 258/97 of the European parliament and of the council and commission regulation (EC) No 1852/2001. Official journal of the European union. Available at: https://eur-lex.europa.eu/eli/reg/2015/2283 (Accessed July 21, 2023)."}, {"Citation": "Evans D. G. (2020). Medical fraud, mislabeling, contamination: all common in CBD products. Mo Med. 117, 394\u2013399.", "ArticleIdList": ["PMC7723146", "33311737"]}, {"Citation": "Fittler A., Vida R. G., R\u00e1dics V., Botz L. (2018). A challenge for healthcare but just another opportunity for illegitimate online sellers: dubious market of shortage oncology drugs. PLoS One 13, e0203185. 10.1371/journal.pone.0203185", "ArticleIdList": ["10.1371/journal.pone.0203185", "PMC6112670", "30153304"]}, {"Citation": "\nFood and Drug Administration (2019). External peer review (letter) of safety of CBD in humans - a literature review conducted on publicly available data through. Available at: https://www.fda.gov/media/152317/download (Accessed July 21, 2023)."}, {"Citation": "\nFood and Drug Administration (2021). Warning Letters and test results for cannabidiol-related products. Available at: https://www.fda.gov/news-events/public-health-focus/warning-letters-and-test-results-cannabidiol-related-products (Accessed July 21, 2023)."}, {"Citation": "Freeman T. P., Hindocha C., Green S. F., Bloomfield M. A. P. (2019). Medicinal use of cannabis based products and cannabinoids. BMJ 365, l1141. 10.1136/bmj.l1141", "ArticleIdList": ["10.1136/bmj.l1141", "PMC6447998", "30948383"]}, {"Citation": "Govindarajan R. K., Mishra A. K., Cho K.-H., Kim K.-H., Yoon K. M., Baek K.-H. (2023). Biosynthesis of phytocannabinoids and structural insights: a review. Metabolites 13, 442. 10.3390/metabo13030442", "ArticleIdList": ["10.3390/metabo13030442", "PMC10051821", "36984882"]}, {"Citation": "G\u00fclck T., M\u00f8ller B. L. (2020). Phytocannabinoids: origins and biosynthesis. Trends Plant Sci. 25, 985\u20131004. 10.1016/j.tplants.2020.05.005", "ArticleIdList": ["10.1016/j.tplants.2020.05.005", "32646718"]}, {"Citation": "Gurley B. J., Murphy T. P., Gul W., Walker L. A., ElSohly M. (2020). Content versus label claims in cannabidiol (CBD)-Containing products obtained from commercial outlets in the state of Mississippi. J. Diet. Suppl. 17, 599\u2013607. 10.1080/19390211.2020.1766634", "ArticleIdList": ["10.1080/19390211.2020.1766634", "32431186"]}, {"Citation": "Hazekamp A. (2018). The trouble with CBD oil. Med. Cannabis Cannabinoids 1, 65\u201372. 10.1159/000489287", "ArticleIdList": ["10.1159/000489287", "PMC8489347", "34676324"]}, {"Citation": "Hazekamp A., Epifanova S. (2017). Grote variatie in samenstelling cannabisolie noopt tot regels. Pharm. Weekbl. 152, 16\u201318."}, {"Citation": "\nHealth Canada (2022). Review of cannabidiol in health products containing cannabis from the science advisory committee on health products containing cannabis. Available at: https://www.canada.ca/en/health-canada/corporate/about-health-canada/public-engagement/external-advisory-bodies/health-products-containing-cannabis/review-cannabidiol-health-products-containing-cannabis.html (Accessed July 21, 2023)."}, {"Citation": "Herbst J., Musgrave G. (2020). Respiratory depression following an accidental overdose of a CBD-labeled product: a pediatric case report. J. Am. Pharm. Assoc. 60, 248\u2013252. 10.1016/j.japh.2019.09.023", "ArticleIdList": ["10.1016/j.japh.2019.09.023", "31767538"]}, {"Citation": "Hesami M., Pepe M., Baiton A., Jones A. M. P. (2023). Current status and future prospects in cannabinoid production through in vitro culture and synthetic biology. Biotechnol. Adv. 62, 108074. 10.1016/j.biotechadv.2022.108074", "ArticleIdList": ["10.1016/j.biotechadv.2022.108074", "36481387"]}, {"Citation": "Huestis M. A., Solimini R., Pichini S., Pacifici R., Carlier J., Busard\u00f2 F. P. (2019). Cannabidiol adverse effects and toxicity. Curr. Neuropharmacol. 17, 974\u2013989. 10.2174/1570159X17666190603171901", "ArticleIdList": ["10.2174/1570159X17666190603171901", "PMC7052834", "31161980"]}, {"Citation": "Hughes B., Vandam L., Mounteney J., Griffiths P. (2022). Regulatory approaches to cannabidiol in the European Union: are market developments sowing the seeds of confusion? Addict. (Abingdon, Engl. 117, 3\u20134. 10.1111/add.15587", "ArticleIdList": ["10.1111/add.15587", "34382260"]}, {"Citation": "\nHungarian National Institute of Pharmacy and Nutrition (2022). Statement regarding Hemp and CBD products in Hungary. Available at: https://ogyei.gov.hu/dynamic/cbd_allasfoglalas_0720.pdf (Accessed July 21, 2023)."}, {"Citation": "Johnson E., Kilgore M., Babalonis S. (2022a). Cannabidiol (CBD) product contamination: quantitative analysis of \u03949-tetrahydrocannabinol (\u03949-THC) concentrations found in commercially available CBD products. Drug Alcohol Depend. 237, 109522. 10.1016/j.drugalcdep.2022.109522", "ArticleIdList": ["10.1016/j.drugalcdep.2022.109522", "PMC9899037", "35690015"]}, {"Citation": "Johnson E., Kilgore M., Babalonis S. (2022b). Label accuracy of unregulated cannabidiol (CBD) products: measured concentration vs. label claim. J. Cannabis Res. 4, 28. 10.1186/s42238-022-00140-1", "ArticleIdList": ["10.1186/s42238-022-00140-1", "PMC9169299", "35658956"]}, {"Citation": "\nKalant H., Porath-Waller A. (2016). Clearing the smoke on cannabis. Available at: https://www.ccsa.ca/clearing-smoke-cannabis-medical-use-cannabis-and-cannabinoids-update (Accessed July 21, 2023)."}, {"Citation": "Kirilov B., Zhelyazkova M., Petkova-Gueorguieva E., Momekov G. (2020). Regulation and marketing of cannabidiol-containing products in European countries. Pharmacists\u2019 knowledge in Bulgaria. Biotechnol. Biotechnol. Equip. 34, 1158\u20131165. 10.1080/13102818.2020.1824620", "ArticleIdList": ["10.1080/13102818.2020.1824620"]}, {"Citation": "Ku\u0161ar A., \u017dmitek K., L\u00e4hteenm\u00e4ki L., Raats M. M., Pravst I. (2021). Comparison of requirements for using health claims on foods in the European Union, the USA, Canada, and Australia/New Zealand. Compr. Rev. Food Sci. Food Saf. 20, 1307\u20131332. 10.1111/1541-4337.12716", "ArticleIdList": ["10.1111/1541-4337.12716", "33565710"]}, {"Citation": "Lachenmeier D. W., Sproll C., Walch S. G. (2023). Does cannabidiol (CBD) in food supplements pose a serious health risk? Consequences of the European food safety authority (EFSA) clock stop regarding novel food authorisation. Psychoactives 2, 66\u201375. 10.3390/psychoactives2010005", "ArticleIdList": ["10.3390/psychoactives2010005"]}, {"Citation": "Liebling J. P., Clarkson N. J., Gibbs B. W., Yates A. S., O\u2019Sullivan S. E. (2022). An analysis of over-the-counter cannabidiol products in the United Kingdom. Cannabis Cannabinoid Res. 7, 207\u2013213. 10.1089/can.2019.0078", "ArticleIdList": ["10.1089/can.2019.0078", "PMC9070743", "33998849"]}, {"Citation": "Messina F., Rosati O., Curini M., Marcotullio M. C. (2015). Cannabis and bioactive cannabinoids. Cannabis Bioact. Cannabinoids, 17\u201357. 10.1016/B978-0-444-63473-3.00002-2", "ArticleIdList": ["10.1016/B978-0-444-63473-3.00002-2"]}, {"Citation": "Miller O. S., Elder E. J., Jones K. J., Gidal B. E. (2022). Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: implications for patients and practitioners. Epilepsy Behav. 127, 108514. 10.1016/j.yebeh.2021.108514", "ArticleIdList": ["10.1016/j.yebeh.2021.108514", "34998268"]}, {"Citation": "Nasrin S., Watson C. J. W., Perez-Paramo Y. X., Lazarus P. (2021). Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions. Drug Metab. Dispos. 49, 1070\u20131080. 10.1124/dmd.121.000442", "ArticleIdList": ["10.1124/dmd.121.000442", "34493602"]}, {"Citation": "\nNational Mental Health and Substance Use Policy Laboratory (2023). Substance abuse and mental health services administration: cannabidiol (CBD) \u2013 potential harms, side effects, and unknowns. Publication No. PEP22- 06-04-003. Rockville. Available at: https://store.samhsa.gov/sites/default/files/pep22-06-04-003.pdf (Accessed July 21, 2023)."}, {"Citation": "Oldfield K., Ryan J., Doppen M., Kung S., Braithwaite I., Newton-Howes G. (2021). A systematic review of the label accuracy of cannabinoid-based products in regulated markets: is what\u2019s on the label what\u2019s in the product? Australas. Psychiatry 29, 88\u201396. 10.1177/1039856220965334", "ArticleIdList": ["10.1177/1039856220965334", "33174758"]}, {"Citation": "Olfson M., Wall M. M., Liu S.-M., Blanco C. (2018). Cannabis use and risk of prescription opioid use disorder in the United States. Am. J. Psychiatry 175, 47\u201353. 10.1176/appi.ajp.2017.17040413", "ArticleIdList": ["10.1176/appi.ajp.2017.17040413", "PMC5756122", "28946762"]}, {"Citation": "Pavlovic R., Nenna G., Calvi L., Panseri S., Borgonovo G., Giupponi L., et al. (2018). Quality traits of \u201ccannabidiol oils\u201d: cannabinoids content, terpene fingerprint and oxidation stability of European commercially available preparations. Molecules 23, 1230. 10.3390/molecules23051230", "ArticleIdList": ["10.3390/molecules23051230", "PMC6100014", "29783790"]}, {"Citation": "Sainz Martinez A., Lanaridi O., Stagel K., Halbwirth H., Schn\u00fcrch M., Bica-Schr\u00f6der K. (2023). Extraction techniques for bioactive compounds of cannabis. Nat. Prod. Rep. 40, 676\u2013717. 10.1039/d2np00059h", "ArticleIdList": ["10.1039/d2np00059h", "36625451"]}, {"Citation": "Sarma N. D., Waye A., ElSohly M. A., Brown P. N., Elzinga S., Johnson H. E., et al. (2020). Cannabis inflorescence for medical purposes: USP considerations for quality attributes. J. Nat. Prod. 83, 1334\u20131351. 10.1021/acs.jnatprod.9b01200", "ArticleIdList": ["10.1021/acs.jnatprod.9b01200", "32281793"]}, {"Citation": "Schlag A. K., Zafar R. R., Lynskey M. T., Athanasiou-Fragkouli A., Phillips L. D., Nutt D. J. (2022). The value of real world evidence: the case of medical cannabis. Front. Psychiatry 13, 1027159. 10.3389/fpsyt.2022.1027159", "ArticleIdList": ["10.3389/fpsyt.2022.1027159", "PMC9669276", "36405915"]}, {"Citation": "Schneider S. (2021). Quality assessment of cannabidiol rich cannabis extracts purchased on the internet. Forensic Sci. Addict. Res. 5. 10.31031/FSAR.2021.05.000620", "ArticleIdList": ["10.31031/FSAR.2021.05.000620"]}, {"Citation": "Sholler D. J., Schoene L., Spindle T. R. (2020). Therapeutic efficacy of cannabidiol (CBD): a review of the evidence from clinical trials and human laboratory studies. Curr. Addict. Rep. 7, 405\u2013412. 10.1007/s40429-020-00326-8", "ArticleIdList": ["10.1007/s40429-020-00326-8", "PMC7880228", "33585159"]}, {"Citation": "Soleymanpour M., Saderholm S., Kavuluru R. (2021). Therapeutic claims in cannabidiol (CBD) marketing messages on twitter, IEEE International Conference on Bioinformatics and Biomedicine (BIBM), USA, July 21, 2021 IEEE, 3083. 10.1109/BIBM52615.2021.9669404", "ArticleIdList": ["10.1109/BIBM52615.2021.9669404", "PMC8794048", "35096472"]}, {"Citation": "Spindle T. R., Sholler D. J., Cone E. J., Murphy T. P., ElSohly M., Winecker R. E., et al. (2022). Cannabinoid content and label accuracy of hemp-derived topical products available online and at national retail stores. JAMA Netw. Open 5, e2223019. 10.1001/jamanetworkopen.2022.23019", "ArticleIdList": ["10.1001/jamanetworkopen.2022.23019", "PMC9301515", "35857320"]}, {"Citation": "\nStevenson R. (2018). Flash report on cannabis in California. Am. Lab. Available at: https://www.americanlaboratory.com/Blog/352371-Flash-Report-on-Cannabis-in-California/(Accessed July 21, 2023)."}, {"Citation": "\nThe Committee on Toxicity of Chemicals in Food (2021). Updated position paper on the potential risk of CBD in CBD food products. Available at: https://cot.food.gov.uk/sites/default/files/2021-08/CBD%20Position%20Paper%20updated%20July%202021.pdf (Accessed July 21, 2023)."}, {"Citation": "Thomas B. F., ElSohly M. A. (2016). \u201cBiosynthesis and pharmacology of phytocannabinoids and related chemical constituents,\u201d in The analytical chemistry of cannabis (China: Elsevier; ), 27\u201341. 10.1016/B978-0-12-804646-3.00002-3", "ArticleIdList": ["10.1016/B978-0-12-804646-3.00002-3"]}, {"Citation": "VanDolah H. J., Bauer B. A., Mauck K. F. (2019). Clinicians\u2019 guide to cannabidiol and hemp oils. Mayo Clin. Proc. 94, 1840\u20131851. 10.1016/j.mayocp.2019.01.003", "ArticleIdList": ["10.1016/j.mayocp.2019.01.003", "31447137"]}, {"Citation": "Vandrey R., Raber J. C., Raber M. E., Douglass B., Miller C., Bonn-Miller M. O. (2022). Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA 313, 2491\u20132493. 10.1001/jama.2015.6613", "ArticleIdList": ["10.1001/jama.2015.6613", "26103034"]}, {"Citation": "Vida R. G., Fittler A., Mikulka I., \u00c1brah\u00e1m E., S\u00e1ndor V., Kil\u00e1r F., et al. (2017). Availability and quality of illegitimate somatropin products obtained from the Internet. Int. J. Clin. Pharm. 39, 78\u201387. 10.1007/s11096-016-0398-y", "ArticleIdList": ["10.1007/s11096-016-0398-y", "27888454"]}, {"Citation": "Vida R. G., Fittler A., Somogyi-V\u00e9gh A., Po\u00f3r M. (2019). Dietary quercetin supplements: assessment of online product informations and quantitation of quercetin in the products by high-performance liquid chromatography. Phytother. Res. 33, 1912\u20131920. 10.1002/ptr.6382", "ArticleIdList": ["10.1002/ptr.6382", "31155780"]}, {"Citation": "Whiting P. F., Wolff R. F., Deshpande S., Di Nisio M., Duffy S., Hernandez A. V., et al. (2015). Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313, 2456\u20132473. 10.1001/jama.2015.6358", "ArticleIdList": ["10.1001/jama.2015.6358", "26103030"]}, {"Citation": "\nWoodcock J. (2023). FDA concludes that existing regulatory frameworks for foods and supplements are not appropriate for cannabidiol, will work with congress on a new way forward. Food Drug Adm. Available at: https://www.fda.gov/news-events/press-announcements/fda-concludes-existing-regulatory-frameworks-foods-and-supplements-are-not-appropriate-cannabidiol (Accessed July 21, 2023)."}, {"Citation": "Zenone M. A., Snyder J., Crooks V. (2021). Selling cannabidiol products in Canada: a framing analysis of advertising claims by online retailers. BMC Public Health 21, 1285. 10.1186/s12889-021-11282-x", "ArticleIdList": ["10.1186/s12889-021-11282-x", "PMC8248754", "34210299"]}]}], "History": [{"Year": "2023", "Month": "8", "Day": "6"}, {"Year": "2023", "Month": "11", "Day": "27"}, {"Year": "2024", "Month": "1", "Day": "9", "Hour": "6", "Minute": "42"}, {"Year": "2024", "Month": "1", "Day": "9", "Hour": "6", "Minute": "41"}, {"Year": "2024", "Month": "1", "Day": "9", "Hour": "3", "Minute": "47"}, {"Year": "2023", "Month": "12", "Day": "14"}], "PublicationStatus": "epublish", "ArticleIdList": ["38192407", "PMC10773908", "10.3389/fphar.2023.1273540", "1273540"]}}]}